XW0J3LA
Introduction Coronary Artery, One Artery to New Technology Group 10 with Paclitaxel-Coated Balloon Technology, Four or More Balloons, Percutaneous Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | X New Technology |
| Body System | W Anatomical Regions |
| Operation | 0 Introduction |
| Body Part | J Coronary Artery, One Artery |
| Approach | 3 Percutaneous |
| Device | L Paclitaxel-Coated Balloon Technology, Four or More Balloons |
| Qualifier | A New Technology Group 10 |
Operation Definition
Putting in or on a therapeutic, diagnostic, nutritional, physiological, or prophylactic substance except blood or blood products
Procedure Overview
This family covers putting a therapeutic, diagnostic, nutritional, or preventive substance into or onto a body region, using a product recently approved under the New Technology pathway rather than an established drug or agent. It is not tied to one organ system but to broader anatomical regions, which is used when the substance is delivered in a way that does not target a single specific body part.
Clinically, this might apply to a patient receiving a newly approved anti-infective, an engineered biologic, or another agent whose novelty is what earns it separate tracking, often because it addresses a resistant infection or a condition that standard substances do not adequately treat.
Anatomy & Axis Detail
Coronary Artery, One Artery
A single coronary artery is targeted for Introduction procedures under New Technology when a novel substance, such as an investigational agent intended to affect vessel wall biology or local perfusion, is delivered directly into that one artery, typically via catheter during a cardiac catheterization procedure. Because coronary arteries supply blood directly to the myocardium, introducing a substance here carries implications for cardiac perfusion and requires careful technique to avoid vessel injury or embolization. This code applies specifically when only one coronary artery is treated, distinguishing it from procedures involving two arteries, and the qualifier identifies the particular New Technology substance used. Documentation should clearly specify that a single vessel, rather than multiple coronary arteries, received the introduced agent.
Approach: Percutaneous
In New Technology, Percutaneous describes entry into the body via needle or instrument puncture through the skin or a mucous membrane, without a surgical incision, mirroring the same concept in Medical and Surgical. It is distinguished from Open access, which requires a full incision, and from Percutaneous Endoscopic, which adds visualization through the puncture site.
Device / Substance / Technology: Paclitaxel-Coated Balloon Technology, Four or More Balloons
This value specifies use of paclitaxel-coated balloon angioplasty in which four or more balloons were used during the procedure, typically reflecting treatment of extensive or multiple vessel segments. It caps the balloon-count series alongside the one-, two-, and three-balloon values, all of which use the same drug-coated balloon technology but are distinguished purely by how many balloons the procedure required.
Qualifier: New Technology Group 10
New Technology Group 10 flags a procedure as part of the 2023 batch of add-on codes recognized under the New Technology section. The value itself carries no information about the device or drug involved; that comes from the table, body part, and approach values alongside it. Coders should not confuse it with Group 9 or Group 11, which cover the cohorts approved in the years immediately before and after.
Coding & Documentation
Coders need the medication administration record or physician note to name the specific substance given and confirm it is one recognized under the current New Technology list, since this family exists specifically to track these products separately from routine drug administration. The route and anatomical region also need to be clearly stated.
A common error is coding a routine medication administration under this family simply because it sounds unfamiliar, when in fact only substances formally approved under the New Technology pathway qualify. Another is missing the code entirely when a newly approved agent is documented only by a shorthand or trade name the coder does not recognize.
Commonly Confused With
This is frequently confused with standard Administration section codes used for everyday medications and fluids. The distinguishing factor is strictly whether the substance itself has New Technology approval, since the delivery method and clinical intent can look identical to a routine medication given for the same reason.